Thompson N., Lyons J. “Recent progress in targeting the Raf/MEK/ERK pathway with inhibitors in cancer drug discovery.” Current Opinion in Pharmacology 5, no. 4 2005: 350–356. DOI: 10.1016/j.coph.2005.04.007.

/in ,

Thompson N., Lyons J. “Recent progress in targeting the Raf/MEK/ERK pathway with inhibitors in cancer drug discovery.” Current Opinion in Pharmacology 5, no. 4 2005: 350–356. DOI: 10.1016/j.coph.2005.04.007.

Gill, A. L. “New Lead Generation Strategies for Protein Kinase Inhibitors – Fragment Based Screening Approaches.” Mini-Reviews in Medicinal Chemistry 4, no. 3 2004: 301-311.

/in ,

Gill, A. L. “New Lead Generation Strategies for Protein Kinase Inhibitors – Fragment Based Screening Approaches.” Mini-Reviews in Medicinal Chemistry 4, no. 3 2004: 301-311.

Patel, S., et al. “Apo and Inhibitor Complex Structures of BACE (β-secretase).” Journal of Molecular Biology 343, no. 2 2004: 407–416. DOI: 10.1016/j.jmb.2004.08.018.

/in ,

Patel, S., et al. “Apo and Inhibitor Complex Structures of BACE (β-secretase).” Journal of Molecular Biology 343, no. 2 2004: 407–416. DOI: 10.1016/j.jmb.2004.08.018.

Rees, D.C., et al. “Fragment-based lead discovery.” Nature Reviews Drug Discovery 3 2004: 660-672. DOI: 10.1038/nrd1467.

/in ,

Rees, D.C., et al. “Fragment-based lead discovery.” Nature Reviews Drug Discovery 3 2004: 660-672. DOI: 10.1038/nrd1467.

Tickle, I., et al. “High-throughput protein crystallography and drug discovery.” Chemical Society Reviews 33, no. 8 2004: 558-565. DOI: 10.1039/B314510G.

/in ,

Tickle, I., et al. “High-throughput protein crystallography and drug discovery.” Chemical Society Reviews 33, no. 8 2004: 558-565. DOI: 10.1039/B314510G.

Verdonk M. L., Hartshorn, M. J. “Structure-guided fragment screening for lead discovery.” Current Opinion in Drug Discovery and Development 7 2004: 404-410.

/in ,

Verdonk M. L., Hartshorn, M. J. “Structure-guided fragment screening for lead discovery.” Current Opinion in Drug Discovery and Development 7 2004: 404-410.

Verdonk, M. L., et al. “Virtual Screening Using Protein−Ligand Docking: Avoiding Artificial Enrichment.” Journal of Chemical Information and Modeling 44, no. 3 2004: 793–806. DOI: 10.1021/ci034289q.

/in ,

Verdonk, M. L., et al. “Virtual Screening Using Protein−Ligand Docking: Avoiding Artificial Enrichment.” Journal of Chemical Information and Modeling 44, no. 3 2004: 793–806. DOI: 10.1021/ci034289q.

Williams, P. A., et al. “Crystal Structures of Human Cytochrome P450 3A4 Bound to Metyrapone and Progesterone.” Science 305, no. 5684 2004: 683-686. DOI: 10.1126/science.1099736.

/in ,

Williams, P. A., et al. “Crystal Structures of Human Cytochrome P450 3A4 Bound to Metyrapone and Progesterone.” Science 305, no. 5684 2004: 683-686. DOI: 10.1126/science.1099736.

Birch, L., et al. “Sensitivity of molecular docking to induced fit effects in influenza virus neuraminidase.” Journal of Computer-Aided Molecular Design 16, no. 12 2003: 855-869. DOI: 10.1023/A:1023844626572.

/in ,

Birch, L., et al. “Sensitivity of molecular docking to induced fit effects in influenza virus neuraminidase.” Journal of Computer-Aided Molecular Design 16, no. 12 2003: 855-869. DOI: 10.1023/A:1023844626572.

Congreve, M.S. et al. “Detection of Ligands from a Dynamic Combinatorial Library by X-ray Crystallography.” Angewandte Chemie International Edition 42, no. 37 2003: 4479–4482. DOI: 10.1002/anie.200351951.

/in ,

Congreve, M.S. et al. “Detection of Ligands from a Dynamic Combinatorial Library by X-ray Crystallography.” Angewandte Chemie International Edition 42, no. 37 2003: 4479–4482. DOI: 10.1002/anie.200351951.